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ABBREVIATIONS 
ELISA, enzyme-linked immunosorbent assay 
ETEC, enterotoxigenic Escherichia coli 
Fab, antigen binding fragment  
Fc, crystallizable fragment  
GdnHCl, guanidine hydrochloride  
HC, heavy chain  
IgG, immunoglobulin G 
LC, light chain 
LT, heat labile enterotoxin 
mAb, monoclonal antibody 
MW, molecular weight 
PEG, polyethylene glycol 
PTM, post translational modifications 
SC, secretory component 
SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
SE-HPLC, size exclusion high performance liquid chromatography 
SGF, simulated gastric fluid 
sIgA, secretory immunoglobulin A 
SV-AUC, sedimentation velocity analytical ultracentrifugation
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ABSTRACT 
Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrheal disease in 
children in developing countries, and there are no licensed vaccines to protect against 
ETEC. Passive immunization by oral delivery of ETEC-specific secretory IgAs (sIgAs) 
could potentially provide an alternative approach for protection in targeted populations. 
In this study, a series of physiochemical techniques and an in vitro gastric digestion 
model were used to characterize and compare key structural attributes and stability 
profiles of three anti-heat labile enterotoxin monoclonal antibodies (sIgA1, sIgA2 and 
IgG1 produced in CHO cells). The mAbs were evaluated in terms of primary structure, 
N-linked glycan profiles, size and aggregate content, relative apparent solubility, 
conformational stability, and in vitro antigen binding. Compared to IgG1 mAb, sIgA1 and 
sIgA2 mAbs showed increased sample heterogeneity, especially in terms of N-glycan 
composition and the presence of higher molecular weight species. The sIgA mAbs 
showed overall better physical stability and were more resistant to loss of antigen 
binding activity during incubation at low pH, 37°C with pepsin. These results are 
discussed in terms of future challenges to design stable, low-cost formulations of sIgA 
mAbs as an oral supplement for passive immunization to protect against enteric 
diseases in the developing world. 
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INTRODUCTION 
Diarrheal diseases are the second leading cause of death in developing 
countries, especially in Sub-Saharan Africa and South Asia,1-3 with ~0.6 million children 
under 5 years of age dying each year due to complications caused by severe 
diarrhea.4,5 A major cause of diarrhea is from drinking water contaminated by 
pathogenic bacteria, viruses, or parasites.4 Enterotoxigenic Escherichia coli (ETEC) is 
the most common bacterial cause of diarrhea-associated mortality, which leads to 
approximately one quarter of all diarrheal episodes for infants and children less than 5-
years of age.6-9 To further complicate these problems, enhanced antibiotic resistance 
has been found in many ETEC strains.10-12 Thus, the development of an ETEC vaccine 
is considered the most effective and feasible strategy to prevent diarrheal diseases 
among children in developing countries,13,14 and has become a high priority for the 
World Health Organization.15 Currently, however, there are no ETEC vaccines 
commercially available and there are numerous scientific challenges (e.g., 
heterogeneity of potential target antigens,4 poor mucosal immunogenicity responses, 
and potential safety issues of with antigens) as well as cost hurdles (e.g., develop, 
manufacture and commercialize for use in the developing world) that impede ETEC 
vaccine development.7,16  
Due to these challenges, there is growing interest in the use of passive 
immunization strategies to treat ETEC-induced diarrheal diseases in targeted 
populations by oral delivery of neutralizing immunoglobulins. For example, local delivery 
of antibodies that bind and neutralize ETEC in the GI tract could be utilized to prevent 
infection. Multiple virulence factors from ETEC have been recognized as potential 
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antigens for passive immunity,10,17 including secretion heat-labile enterotoxin (LT) which 
directly induces diarrhea by prompting solute retention and loss of water absorption in 
the intestinal lumen. LT is a heterohexameric A-B subunit toxin comprised of a 
catalytically active A-subunit and five B subunits.17 Subunit A has ADP-ribosylation 
activity, which covalently modifies the subunit of the GTP-binding protein (Gs), leading 
to the constitutive activation of adenylate cyclase and production of 3’,5’-cyclic AMP 
(cAMP).18 Consequently, continuous release of chloride and water into intestinal lumen 
occurs causing watery diarrhea. The five B subunits mediate LT binding to glycolipid 
and glycoprotein receptors on host cells.18 Thus, antibody-induced neutralization of LT 
enzymatic activity and inhibition of adhesion could potentially be effective in controlling 
ETEC infection.  
 Secretory IgA (sIgA) antibodies are of particular interest for passive immunization 
during oral administration due to their natural abundance in secretions and mucosal 
surfaces.19 As the most prevalent immunoglobulin isotype in mucosal membranes, 
secretory IgAs (sIgAs) play crucial roles in protecting gut mucosal surfaces from 
pathogens and toxins.20-22 Secretory IgAs function to promote clearance of pathogens, 
maintenance of intestinal homeostasis, direct neutralization of bacterial virulence factors 
(e.g., enterotoxins), and modulation of proinflammatory responses.20-23 Therefore, sIgA 
mAbs are a potential therapeutic platform for passive immunization by oral 
administration 24 . Secretory IgA antibodies consist of dimeric IgG-like molecules, linked 
by a joining chain (J-chain), and complexed with a secretory component (SC) chain25. 
The SC protein is acquired as the polymeric immunoglobulin receptor cleaves upon 
transport across epithelial cells into mucosal surfaces and secretions. Secretory IgA 
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antibodies are inherently more resistant to proteolysis by digestive enzymes when 
compared to IgG in the gastrointestinal tract.26,27 
In this work, three anti-LT isotype variants (sIgA1, sIgA2 and IgG1) were 
expressed and purified from CHO cells in quantities of ~5-10 mg. A series of 
physiochemical methods were developed (to accommodate limited availability of 
material) and utilized for preformulation characterization of anti-LT sIgA1, sIgA2, and 
IgG1 mAbs including evaluating various structural attributes (i.e., primary structure, 
post-translational modifications, size heterogeneity/aggregation, conformational stability, 
relative solubility, and antibody binding), and identifying several key structural attributes 
of the sIgA mAbs to monitor during stability assessments. To this end, we examined the 
stability profile of the three anti-LT mAbs under conditions that mimic the gastric phase 
of oral delivery using simulated gastric fluids in a modified, scaled-down version of an in 
vitro gastric digestive model. These results are evaluated in terms of relative rank-
ordering of the pharmaceutical stability of the three anti-LT mAbs from the point of view 
of future formulation development work to optimize both storage stability as well as 
stability during oral delivery.  
 
MATERIALS AND METHODS 
Sample Preparation 
The three anti-heat labile toxin (LT) immunoglobulins (sIgA1, sIgA2, and IgG1) 
were expressed in CHO cells and purified by MassBiologics (University of 
Massachusetts Medical School, Boston, MA). The antibodies were prepared in 10 mM 
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sodium phosphate, 150 mM NaCl, pH 7.2 (phosphate-buffered saline, PBS) and stored 
at 2-8°C. Protein concentration was determined by ELISA using known concentrations 
of sIgA1, sIgA2 or IgG1 as standards. When the protein concentration was determined 
by UV-visible spectroscopy, extinction coefficients were calculated based on the primary 
sequences28 as 1.49, 1.49, 1.64 mL·mg-1·cm-1 for sIgA1 sIgA2 and IgG1, respectively.  
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Twenty µL of each 0.2 mg/mL Ig sample was mixed with or without 1 µL of 
PNGase F (New England BioLabs, Ipswich, MA) and incubated overnight at 37oC. Both 
deglycosylated and glycosylated Ig samples were reduced with 50 mM dithiothreitol 
(DTT, Invitrogen, Carlsbad, CA) at 70oC for 30 min. Reduced and non-reduced samples 
were then mixed with 4X LDS loading dye (Life Technologies, Grand Island, NY) 
containing 100 mM iodoacetamide (IAM, Life Technologies), and incubated at 100oC for 
5 min. Samples were cooled to room temperature (RT) and separated by SDS-PAGE 
using NuPAGE 10% Bis-tris gels (Life Technologies) and MOPS running buffer (Life 
Technologies) at 150 V for 75 min. Gels were stained with Coomassie Blue R-250 
(Teknova, Hollister, CA) and destained with 40% methanol 10% acetic acid. Gels were 
digitized using an AlphaImager (Protein Simple, Santa Clara, CA) gel imaging system. 
Size Exclusion Chromatography (SEC)  
A Shimadzu Prominence ultra-fast liquid chromatography HPLC system 
equipped with a diode array detector (with absorbance detection at 214 nm) was 
utilized. The system was equilibrated at 0.5 mL/min flow rate in 0.2 M sodium 
phosphate buffer at pH 6.8 for at least 2 hours. Ten µL of each Ig (10 µg total protein) 
was injected and separated by a TOSOH TSKgel G4000SWXL column (8 µm particle 
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size, 7.8 mm ID × 30 cm) for sIgA or a TOSOH TSK-Gel BioAssist G3SWxl column (5 
µm size, 7.8 mm ID × 30 cm) for IgG1 with a corresponding guard column operated at 
ambient temperature (Tosoh Biosciences) using a 30-minute run time. Gel filtration 
molecular weight standards (Bio-Rad, Hercules, CA) were injected before and after the 
Ig sample sets to ensure integrity of the column and HPLC system. Potential presence 
of larger aggregates were determined by running Ig samples with and without the SEC 
column (i.e., protein percentage recovery). Greater than 95% protein recovery was 
obtained for each of the three mAbs by SE-HPLC, indicating minimal loss of protein 
(e.g., larger aggregates) by using optimized SE-HPLC conditions for sIgA vs IgG1. Data 
were analyzed using LC-Solution software (Shimadzu, Kyoto, Japan). 
Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) 
SV-AUC was performed using a Proteome Lab XL-I (Beckman Coulter) analytical 
ultracentrifuge equipped with a scanning ultraviolet-visible optical system. Samples 
were diluted to 0.2 mg/mL in PBS pH 7.2 and transferred into Beckman charcoal-epon 
two sector cells with a 12 mm centerpiece and sapphire windows. All experiments were 
performed at 20oC after at least 1 hour of equilibration after the rotor reached 20oC. SV-
AUC was performed at a rotor speed of 40,000 RPM and with detection at 280 nm. The 
data were analyzed using Sedfit software (Dr. Peter Schuck, NIH). The partial specific 
volume was calculated using Sednterp software (Professor Thomas Laue, University of 
New Hampshire) based on the primary sequence. The buffer density and viscosity used 
in the analysis were also calculated using Sednterp based on the composition of the 
buffer. The density and viscosity of PBS buffer were calculated to be 1.0059 g/mL and 
0.01021 Poise, respectively. A continuous c(s) distribution model was applied with a 
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range from 0 to 15 svedbergs, with a resolution of 300 points per distribution and a 
confidence level of 0.95. Baseline, radial independent noise, and time independent 
noise were fit parameters, while the meniscus and bottom positions were set manually.  
LC-MS Peptide Mapping 
Ninety µl of 0.5 mg/mL Ig samples were reduced with 3 µl of 0.5 M DTT for 30 
min at 80oC and alkylated with 6 µl of 0.5 M IAM for 30 min at 37oC in the dark. The 
samples were then incubated overnight at 37oC with 12 µg of trypsin or chymotrypsin 
(~1:25 enzyme:Ig ratio). The following day, the samples were heated to 98oC for 5 min 
to inactive the enzyme. After cooling, samples were treated with PNGase F (New 
England BioLabs, Ipswich, MA) as described above to remove N-linked 
oligosaccharides. Before LC-MS injections, 0.05% (v/v) trifluoroacetic acid was added, 
and samples were centrifuged for 5 min at 14,000 xg. The peptides from the digested 
protein solution were then separated by reversed phase UHPLC (Thermo Scientific) 
using a C18 column (1.7µm, 2.1 x 150 mm, Waters Corporation) and a 85 min 0-30% B 
gradient (A: H2O and 0.05% trifluoroacetic acid; B: ACN and 0.05% trifluoroacetic acid; 
200 µl/min flow rate). MS was performed using a LTQ-XL ion trap (Thermo Scientific) 
and Xcalibur v2.0 software (Thermo Scientific). The instrument was tuned using a 
standard calibration peptide (Angiotensin II, Sigma) for maximal sensitivity prior to 
running any experiments. The mass spectra were acquired in the LTQ over a mass 
range of m/z 400-1900 using an ion selection threshold of 40,000 counts and a dynamic 
exclusion duration of 5 sec. Raw experimental files were processed using PepFinder 
2.0 software (Thermo Scientific). The database used for this experiment consisted of 
the primary sequences of all Ig molecules. Potential Cys carbamidomethylation, Asn 
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deamidation, and Met oxidation were included in the analysis. Peptide assignments of 
MS/MS spectra were validated using a confidence score of > 95%. 
Total Carbohydrate Analysis 
A glycoprotein carbohydrate estimation kit (Thermo-Fisher #23260) was used to 
determine the total carbohydrate content (both N- and O-linked oligosaccharides) in Ig 
samples as a percentage of total protein mass. Prior to experiments, protein samples 
were buffer exchanged into PBS at pH 7.2 using 30 kD MWCO filters (EMD Millipore, 
Billerica, MA) and a final concentration of 0.25 mg/mL Ig was used in each reaction. The 
recommended procedure provided by the manufacturer was used. Absorbance at 550 
nm was determined using a SpectraMax M5 microtiter plate reader (Molecular Devices). 
Lysozyme, BSA, ovalbumin, Apo-transferrin, fetuin, and α1-acid were used as 
glycoprotein standards to construct a standard curve.  
N-Glycan Oligosaccharide Analysis 
A GlycoWorks RapiFluor-MS N-Glycan Kit (Waters Corporation, Milford, MA) was 
used to identify and quantify N-linked glycans following the manufacturer instructions. 
Briefly, Ig samples were centrifuged at 10,000 rpm for 5 mins, 7.5 µL of 2 mg/mL Igs 
were mixed with 15.3 µL ultrapure water and 6 µL Rapi-surfactant and then heated at 
90oC for 3 min. After cooling to ambient temperature, 1.2 µL of Rapi-PNGase F was 
added and samples were incubated at 50oC for 5 min to release N-linked glycans. 
Labeling was performed by combining oligosaccharide samples with 12 µL RapiFluor-
MS reagent for 5 min. The reaction was diluted in 358 µL of acetonitrile and the reaction 
products purified using a HILIC µElution plate. The plate was washed three times in 
wash buffer (1% formic acid, 90% acetonitrile) and eluted in 90 µL of elution buffer. The 
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samples were further diluted in 310 µL of diluent buffer. Fluor-MS N-glycan analysis was 
performed using an Agilent 1260 Infinity II HPLC system equipped with a 1260 FLD 
detector (Agilent, Santa Clara, CA) and an Agilent 6230 electrospray ionization Time-of-
Flight mass spectrometer (Agilent, Santa Clara, CA). A HILIC AdvanceBio Glycan 
Mapping column (120 Å, 2.1 x 150 mm, 2.7 µm), that was operated at 45oC, was used 
to separate various N-glycans. Fifty µL of prepared samples was injected into LC-MS 
system, with a flow rate of 0.6 mg/mL and a gradient run time of 55 min. Fluorescence 
was obtained using excitation and emission wavelengths of 265 and 425 nm, 
respectively. MS was acquired simultaneously from 400 to 2000 m/z at a constant scan 
rate of one spectrum per second. N-glycans were assigned based on m/z values using 
a N-glycan database,29 and N-glycan quantification was calculated on integration of the 
fluorescence chromatogram. 
Conformational Stability Assessments 
Thermal unfolding experiments were performed with Ig samples diluted in either 
PBS pH 7.2 or buffer exchanged into a modified simulated gastric fluid (SGF) containing 
94mM NaCl, 13mM KCl with 10 mM citrate phosphate (CP) buffer at pH 3.030. Samples 
were then diluted in the corresponding buffer to a final concentration of 0.2 mg/mL. A 
fluorescence plate reader equipped with a charge-coupled device (CCD) detector 
(Fluorescence Innovations, Minneapolis, MN) was used to obtain intrinsic tryptophan 
fluorescence spectra. Twenty µL of each sample were loaded into a 384-well plate 
(Hard-Shell 384- well PCR plates), and overlaid with 2 µL of silicon oil (ThermoFisher 
Scientific, Waltham, MA). Samples were excited at 295 nm (>95% tryptophan emission) 
and the emission spectra were recorded from 300 to 450 nm with an integration time of 
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100 ms. Temperature ramps were programed from 10 to 100oC with an increment of 
2.5oC per step. The mean center of spectra mass (MSM) peak algorithm was used to 
analyze the data to determine the shift in fluorescence peak position as a function of 
temperature.31  
Denaturant unfolding experiments were performed using 8 M stock solution of 
GdnHCl prepared in either PBS pH 7.2 or SGF containing 10 mM CP buffer at pH 3.0. 
Ig samples were buffer exchanged and diluted to a final Ig concentration of 0.2 mg/mL, 
with a series of GdnHCl concentrations from 0 to 5.5 M. Ten µL of each Ig sample was 
transferred to a 384-well plate (Hard-Shell 384-well PCR plates) and incubated at 4oC 
overnight before performing fluorescence measurements as outlined above, but without 
the silicone oil overlay and at a fixed temperature (10oC). Data analysis was performed 
as described above. 
Relative Protein Solubility (Polyethylene Glycol Precipitation Assay) 
Relative solubility of Igs was performed by adapting the method by Gibson et 
al.32 and Toprani et al.33 using smaller volumes. Briefly, 384-well polystyrene filter plates 
(Corning Life Sciences, Corning, NY) were used. Thirty percent w/v PEG10,000 stock 
solutions were prepared in either PBS pH 7.2 or SGF containing 10 mM CP buffer pH 
3.0. Various concentrations of PEG10,000 solutions ranging from 0 to 25% w/v were 
prepared with Ig concentration of 0.2 mg/mL in both buffer conditions. Samples were 
incubated overnight at RT in dark. The next day, plates were centrifuged at 1,233 × g for 
15 min and directly eluted into a clean 384-well plate. Relative protein concentration in 
each well was determined using a SpectraMax M5 plate reader (Molecular Devices) 
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using detection at 214 nm. %PEGmidpt values were then calculated as described 
previously.32 
 
In vitro Model of Gastric Digestion  
To determine the stability of the proteins under simulated gastric conditions, each 
Ig was diluted in simulated gastric fluid (SGF), which was composed of 94 mM NaCl, 13 
mM KCl, 0.15 mM CaCl2, along with 10 mM citrate-phosphate buffer pH 3.5 (added to 
maintain pH). Protein samples were either diluted directly into SGF/CP buffer alone or 
SGF/CP buffer with added bicarbonate buffer (9:1 ratio of the digestion solution and a 
bicarbonate neutralization buffer containing 0.03 M trisodium citrate and 0.3 M sodium 
bicarbonate at pH 8.534) at a final protein concentration of 0.2 mg/mL. The reaction was 
started when the pepsin (2000 U/mL pepsin, Sigma)30 was added to the solution and 
samples were incubated at 37oC for varying amounts of time. The reaction was 
quenched by the addition of 400 mM NaOH to adjust to neutral pH. Samples were then 
analyzed by SDS-PAGE and ELISA. For ELISA analysis, samples were diluted in 
ELISA blocking buffer (0.1% BSA in PBS) at 40 µg/mL and 1 µg/mL of sIgAs and IgG1 
digested samples based on the starting concentration, respectively and stored at -20oC 
until analysis. 
Immobilized Pepsin Digestion 
The Ig samples were diluted in SGF/CP buffer (see composition above) at a final 
concentration of 0.2 mg/mL. Immobilized pepsin-agarose (Thermo-Fisher) was washed 
three times in SGF by centrifugation at 12,000 x g prior to addition to the diluted Ig mAb 
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mixture to a final pepsin concentration of 2000 U/mL. Samples were incubated at 37°C 
with end over end rotation to keep the beads in suspension. Beads were removed by 
centrifugation at 12,000 x g for 1 min upon completion of the desired incubation times, 
and the supernatant was removed. Samples were then neutralized by addition of 
400mM NaOH prior to analysis by SE-HPLC. SE-HPLC was performed as described 
above, but with an injection volume of 25 µl.  
Enzyme-Linked Immunosorbent Assay (ELISA) 
In this work, 96-well affinity immunoassay plates (Thermal Scientific, Rochester, NY) 
were coated with 1.0 µg/mL Heat-Labile Enterotoxin, B subunit (LTB) from E. coli 
(Sigma E8656) in PBS pH 7.2 and incubated overnight at 4oC. The following day, after 
removing coating solution, 96-well plates were filled with 200 µL of ELISA blocking 
buffer (0.1% BSA in PBS) for 2 hours at room temperature. After flicking out blocking 
buffer, digested Ig samples were loaded 1:1 with blocking buffer and 1:1 serial dilutions 
were performed using blocking buffer as the diluent. Samples were incubated for 30 
mins at room temperature. Plates were washed three times with 0.05% Tween-20 in 
PBS, then 50 µL/well of HRP conjugated Goat anti-human Ig protein (Fisher, Southern 
Biotechnology Associates) diluted in blocking buffer (1:15,000 was added and incubated 
for 30 mins at room temperature. Plates were washed as before, and 100 µL/well TMB 
substrate solution (3,3',5,5'-Tetramethylbenzidine (TMB)) was added and incubated for 
5 min at room temperature in the dark. The reaction was quenched with 100 µL/well 1 M 
phosphoric acid. Optical density (OD) was recorded using a SpectraMax M5 microtiter 
plate reader (Molecular Devices) at 450 nm. Antibody binding to LTB by ELISA 
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correlates with functional activity of the antibody as measured by GM1 holotoxin assay 
and Y-1 pathology assay (data not shown). 
 
RESULTS  
Characterization of Purity, Primary Structure and Post-translational Modifications of 
sIgA vs. IgG mAbs 
In this work, we utilized various analytical tools to perform preformulation 
characterization of three anti-LT mAbs (sIgA1, sIgA2 and IgG1) to identify key structural 
attributes of the mAbs to then subsequently monitor for various stability assessments 
and for future formulation development work. As shown schematically in Figure 1A, sIgA 
antibodies are known to be composed of two IgG-like molecules which are disulfide 
linked by a ~16 kDa joining chain (termed the J-chain), and also a ~70 kDa secretory 
component (SC) chain that is complexed via the heavy chains in the Fc domains.25 The 
combined molecular weight of sIgA polypeptide chains is ~380 kDa which increases to 
~435-460 kDa due to 15-20% N-linked and O-linked glycosylation depending upon the 
sIgA subclass (see below). In comparison, IgG antibodies are less structurally complex 
and smaller (~150 kDa with 1-2% N-linked glycosylation). The sIgA antibodies shown 
schematically in Figure 1A are commonly referred to as dimeric sIgA in the literature35 
(we use the terms sIgA and dimeric sIgA interchangeably in this work while we refer to 
the IgG antibody simply as IgG1). There are two main subclasses of sIgAs (sIgA1 and 
sIgA2) which structurally differ primarily in their hinge regions (e.g., length of hinge 
region, disulfide-bonding pattern, and the type and number of attached glycosylation 
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sites)36 as depicted schematically in Figure 1A. Two and three conserved N-linked 
glycans are found on each Fc domain of sIgA1 and sIgA2, respectively, while sIgA2 
also possesses one or two additional N-linked glycans on the CH1 domain. Another key 
structural difference is sIgA1 contains multiple O-glycans on its elongated hinge region, 
while sIgA2 possesses a shorter hinge region that lacks such glycosylation.37 Both 
subclasses contain several N-linked glycosylation sites on the J-chain and SC.38  
SDS-PAGE analysis was performed under non-reducing and reducing 
conditions, both with and without PNGase F treatment to remove N-glycans, as shown 
in Figure 1B. Under non-reduced conditions, both sIgA1 and sIgA2 mAbs displayed 
smear bands with a composition (based on migration within the gel vs MW standards) of 
dimeric sIgA and higher molecular weight (HMW) species. The IgG1 sample migrated 
as primarily a single species at the expected MW of ~150 kDa. For the sIgA1 and sIgA2 
samples, the dimeric sIgA and higher molecular weight (HMW) bands were shown to 
contain covalently cross-linked disulfide bonded species upon comparison to the 
reduced samples (consistent with previous reports).39-41 Under reducing conditions, 
three major components were identified for the sIgA mAb samples: the SC (~70 kDa), 
heavy chain (~50 kDa), and light chain (~25 kDa). Although the J-chain (~16 kDa) was 
not observed by SDS-PAGE (consistent with literature results; see discussion), its 
presence was confirmed by LC-MS peptide mapping (see below). Specifically for sIgA2, 
we also observed two bands at relatively lower molecular weights (~17 kDa and ~40 
kDa), which could represent a sIgA2 fragment (for the ~17 kDa band), rather than J 
chain, due to their disappearance after reduction. The heavy and light chains of the 
PNGase F-treated, reduced sIgAs migrated at slightly lower MW on the gel, indicating 
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deglycosylation of these molecules. As expected, no migration differences were 
observed for the light chain bands independent of PNGase F treatment. In contrast, for 
the reduced IgG1 sample, both heavy (~50 kDa) and light (~25 kDa) chains were 
observed, and small amount of fragments (~17 kDa) were also seen. Since the IgG1 
heavy chain is N-glycosylated (see below), it also displayed lower MW migration after 
PNGase F treatment.  
To confirm the primary sequence and identify potential post-translational 
modifications (PTMs), LC-MS peptide mapping was performed with the three anti-LT 
mAbs. Due to the requirement for PNGase F for successful chromatographic resolution 
(data not shown), contributions of the N-glycans were not detected, and this PTM was 
examined separately (see below). Due to the sequence similarity (>97%) of sIgA1 and 
sIgA2, including both the variable and constant regions, many peptides were similar in 
terms of elution profile (Figure 2A). At the same time, some differences in peptide 
elution profiles were also observed thus demonstrating a unique profile for each sIgA. 
For IgG1, the base peak chromatogram was significantly different when compared to 
the sIgAs, indicating a distinct digestion profile. Therefore, “fingerprint” chromatograms 
were obtained for each of the three mAbs. The sequence coverage obtained for each of 
the polypeptide chains is shown in Figure 2B. Overall, >85% coverage was obtained for 
each polypeptide chain for each mAbs. The light chain displayed the best coverage (97-
100%), the heavy chain coverage was from 83% to 97%, and SC and J chain displayed 
86-87% and 83-96% sequence coverage, respectively. In terms of PTMs, no notable 
chemical modifications on sIgA1 and sIgA2 mAbs were observed. For IgG1, N-terminal 
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pyroglutamic acid formation and C-terminal lysine residual truncation were identified in 
the heavy chain, which are commonly observed PTMs with IgG1 mAbs.42,43 
  Glycosylation of antibodies plays an important role in functional activity (effector 
function and potentially antigen binding) as well as physical properties such as solubility 
and stability.44-47 A combination of total carbohydrate content as well the identification 
and quantification of the N-glycan oligosaccharide profile was determined for each of 
the three anti-LT mAbs. As shown in Figure 3A, a substantial difference in the total 
carbohydrate content between sIgAs mAbs (18.7% and 18.5% for sIgA1 and sIgA2, 
respectively), and IgG1 (1.2%) was observed. This result is consistent with the known 
structure and post-translational modifications of each mAb (Figure 1A). Further analysis 
was performed to identify specific N-glycan type and relative quantification was 
performed by removal and derivatization of the N-glycans followed by chromatographic 
separation with detection by a combination of MS analysis and fluorescence 
measurements (see methods). Twenty-four and twenty-three different N-glycans for 
sIgA1 (Figure 3B) and sIgA2 (Figure 3C) were identified, respectively, with G2+NANA 
and G2F+NANA observed to be the most dominant glycan types. In contrast, as shown 
in Figure 3D, the IgG1 mAb displayed a much simpler N-glycan profile, with 5 major N-
glycan oligosaccharides, in which glycan G0F was the most dominant type (>80%). 
Each N-glycan type and corresponding percent composition found in each anti-LT mAb 
are summarized in Figure 4. It can be seen that the N-linked oligosaccharide 
composition and distribution greatly differs between the sIgA and IgG1 mAbs, as well as 
between the sIgA1 and sIgA2 mAbs. 
Characterization of Size and Aggregation Profile of sIgA vs IgG mAbs 
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In addition to size analysis under denaturing conditions by SDS-PAGE (see 
Figure 1B), size distribution profiles under non-denaturing conditions were determined 
for each of the three anti-LT mAbs using two orthogonal methods, SV-AUC and SE-
HPLC, as shown in Figure 5A and 5B, respectively. Two size categories (main peak and 
higher-order molecular weight (HMW) species) were used to classify the size 
distribution of each sample. To be consistent with literature nomenclature, the main 
peak of the sIgAs is referred to as dimeric sIgA while the main peak for IgG is simply 
referred to as IgG1. Multiple species were identified by both SV-AUC and SE-HPLC, 
with SV-AUC displaying superior peak resolution between the main peak and the HMW 
species. Overall, similar percent composition results were observed in comparing SV-
AUC and SE-HPLC size distribution results after peak area integration (Figure 5C). Both 
sIgA1 and sIgA2 samples displayed a combination of main peak (dimeric sIgA) as well 
as relatively higher amounts of HMW species in solution (~50% and ~80% of total 
protein peak area, respectively, for sIgA1 and sIgA2 samples). For IgG1, a more 
homogeneous peak distribution was observed (it should be noted that to optimize 
separation of different species and percent recovery, different SEC columns were 
employed for the sIgA vs. IgG1 samples, and thus the IgG1 eluted at an earlier retention 
time; see methods) with <10% of total protein peak area in the form of HMW species. 
For each of the observed species, the molecular weight values were estimated, based 
on sedimentation coefficient values and comparison to the gel filtration standards for 
SV-AUC and SE-HPLC, respectively. As shown in Supplemental Table S1, the 
estimated molecular weight values of the main peak were calculated to be~430 kDa 
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(with values ranging from 414-441 kDa) for the two sIgA mAbs and ~150 kDa for the 
IgG1 mAb.  
Conformational Stability and Relative Solubility Assessment of sIgA vs IgG mAbs  
 The sIgA1, sIgA2 and IgG1 mAbs were then compared in terms of their 
conformational stability and relative solubility profiles under two different pH solution 
conditions including pH 7.2 (to evaluate stability/relative solubility under storage 
conditions at neutral pH) and pH 3.0 (to evaluate stability/relative solubility under gastric 
conditions at acidic pH). First, the conformational stability of the mAbs was examined as 
a function of temperature. As shown in Figure 6A, solution pH effects the overall tertiary 
structure of the mAbs as a function of increasing temperature as determined by intrinsic 
Trp fluorescence spectroscopy. Each of the three mAbs has a similar lambda max value 
at 10°C and one major transition was observed to begin at 60-70oC at pH 7.2 for each 
of the mAbs. When the solution pH was decreased to 3.0, however, a red shift was 
observed at 10oC and multiple transitions were detected across the entire temperature 
range, and a red shift was observed at 10oC. These results suggest that the overall 
tertiary structure of each mAb is partially altered under acidic pH solution conditions and 
differences in their temperature melting profiles may be due to differences in partially 
altered structural states. Second, the conformational stability of the three mAbs was 
examined by the addition of increasing amounts of the chemical denaturant guanidine 
hydrochloride (GdnHCl), by monitoring changes in overall tertiary structure of the mAbs 
by fluorescence spectroscopy as shown in Figure 6B. The sIgA1 and sIgA2 mAbs 
showed one broad transition as the GdnHCl concentration was increased with a 
midpoint of ~3M at pH 7.2. At pH 3.0, both sIgA mAbs showed lower conformational 
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stability. Two distinct transitions were observed for IgG1 at pH 7.2, with midpoints of ~2 
and ~4M GdnHCl. Lower conformational stability was also noted at pH 3.0 for the IgG1 
mAb. Finally, in terms of pH effects on size/aggregation profiles, a preliminary SV-AUC 
experiment (n=1) was performed to compare results at pH 7.2 (PBS buffer) to pH 3.0 
(SGF without CP buffer), and no notable differences in the percent area of the major 
peaks (see Figure 5) were noted for either the sIgA1, sIgA2 or IgG mAbs (data not 
shown).  
Interestingly, in terms of relative apparent solubility as measured by PEG-10,000 
precipitation assay, a higher concentration of PEG-10,000 was required at pH 3.0 to 
precipitate each of the three anti-LT mAbs compared to pH 7.2 in the relative rank order 
of sIgA1 > sIgA2 > IgG1 (Figure 6C). In fact, the sIgA1 remained soluble and failed to 
precipitate despite addition of the highest concentration PEG-10,000 (25%, w/v) when 
the solution pH was 3.0. Thus, higher relative apparent solubility was observed for each 
of three mAbs, albeit to various extents, by decreasing the solution pH from 7.2 to 3.0. 
Examination of sIgA vs IgG Stability in an In Vitro Gastric Digestion Model to Mimic Oral 
Administration  
To investigate and compare stability profiles of each of the mAbs under 
conditions that mimic oral delivery, we adapted an in vitro digestion model that focused 
on the gastric phase using simulated adult conditions for food digestion.34 In this 
adapted model, we scaled down the volume requirements and determined the most 
crucial experimental variables on mAb digestion rates including solution pH, digestion 
time, and pepsin concentration (data not shown). We fixed the solution pH to 3.5 (using 
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a low concentration of 10 mM citrate phosphate buffer), optimized the pepsin 
concentration to 2000 U/mL, and monitored digestion in 1 mL solution as a function of 
time at 37°C (see methods section). Three analytical techniques (ELISA, non-reducing 
SDS-PAGE, SE-HPLC) were used to assess the antigen binding activity, purity and size 
of each the anti-LT mAbs (and/or their degradation products) vs. incubation time, 
respectively.  
First, the LT-antigen binding activity of each mAb was assessed by ELISA as a 
function of incubation time in the in vitro digestion model. The ELISA binding activity 
correlated well with antibody activities in functional assays including GM1 holotoxin 
assay and Y-1 pathology assay (data not shown). At time zero, the sIgA1, sIgA2 and 
IgG1 anti-LT mAbs bound the antigen in a concentration dependent manner with a 
midpoint between 0.01 to 0.1 mg/mL mAb (Figure 7A, 7B and 7C, respectively). During 
incubation, a decreased signal (indicating decreasing amounts of mAb binding to the LT 
antigen) was observed for both sIgA1 and sIgA2. Nonetheless, no shift in the midpoint 
was noted and some antigen binding was still observed even after overnight digestion 
(Figure 7 A, B). In contrast, IgG1 lost its LT binding ability to a much greater extent (shift 
in the midpoint values as well as decreased total signal), and much more rapidly, when 
compared to the sIgAs (Figure 7C). The majority of the binding capacity of IgG1 sample 
was lost after 5-10 minutes of digestion. To better compare these results across the 
three anti-LT mAbs, the percent loss of binding signal was calculated and the relative 
loss rates were then compared (Figure 7D). For IgG1, the loss of mAb binding to LT 
antigen was rapid compared to the slower rates observed for both of the sIgAs. The co-
addition of sodium bicarbonate buffer, which neutralizes the acidic pH leading to 
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irreversible inactivation of pepsin,48,49 resulted in ~100% retention of LT binding even 
after overnight incubation in the in vitro gastric digestion model as shown in Figure 7D. 
Second, non-reducing SDS-PAGE was performed on the same sIgA1, sIgA2 and 
IgG1 samples incubated in the in vitro gastric digestion model (Figure 8). The intact 
sIgA1 mAb (containing dimeric sIgA and HMW species as described above) was 
gradually digested, and a series of digestion byproducts were observed including a 
major species ~100 kDa, which presumably corresponds to the F(ab’)2 fragment (Figure 
7A). After 3 hours, sIgA1 degraded mostly to the ~100 kDa species. This result is 
consistent with known Fc susceptibility to pepsin digestion into smaller MW peptides 
while the more resistant F(ab’)2 fragment remains intact.
50,51 As expected, the intact 
sIgA1 species were essentially completely protected with co-addition of a sodium 
bicarbonate buffer (Figure 8A). Overall similar observations were made with the sIgA2 
mAb as shown in Figure 8B, however, one difference was noted: in addition to the major 
digestion species of F(ab’)2, another protein species was detected at ~50 kDa which 
was likely the Fab fragment. Addition of the bicarbonate buffer played a similar role in 
protecting sIgA2 from digestion by increasing solution pH. In contrast, IgG1 displayed 
an accelerated digestion profile when compared to the sIgAs (Figure 8C). After the first 
time point (5 min), almost all of the IgG1 was digested to F(ab’)2 fragments, and these 
remained after overnight incubation (Figure 8C). The protective effect of bicarbonate 
buffer addition was also observed for IgG1. To more directly compare digestion profiles 
of the three mAbs by non-reduced SDS-PAGE, densitometry analysis of the native mAb 
band was performed (Figure 8D). Although each of the intact mAbs were fully digested 
after overnight incubation (without addition of bicarbonate buffer), the rate of digestion 
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of the sIgAs was much slower when compared to IgG1, indicating an increased 
resistance to acidic pH and pepsin digestion.  
Finally, SE-HPLC was also used to determine the size degradation profile of the 
three anti-LT mAbs (under non-denaturing conditions) by quantifying the decrease of 
the intact protein species and increase of the corresponding degradation products 
(Figure 9). In this experiment, immobilized pepsin was utilized to easily remove the 
pepsin from the solution, since pepsin co-eluted with the sIgA degradation products in 
the SEC chromatograms (data not shown). Three major peaks were identified in the 
SEC chromatograms of the sIgA samples: the intact species (containing dimeric sIgA 
and HMW species as described above), large fragments, and small fragments (Figure 
9A). Presumably, native protein is the intact species, while the F(ab’)2 /F(ab) are the 
large fragments and smaller peptide byproducts represent the small fragments. As 
shown in Figure 9A, digestion of intact sIgA1 was observed as a function of time where 
the main peak area decreased at each time point, while there was a concurrent 
increase in the large and small fragments. For sIgA2, similar trends were observed 
(Figure 9B). For IgG1, three peaks were also observed, however, the digestion occurred 
more rapidly (when compared to the sIgAs) based on the reduction of the main peak 
area (Figure 9C). To facilitate comparisons, the percent of intact mAb as a function of 
digestion time was determined. Both sIgA1 and sIgA2 demonstrated greater resistance 
to pepsin digestion when compared to IgG1, with no notable differences between sIgA1 
and sIgA2 under these conditions (Figure 9D). 
Comparisons of Stability/Solubility Profiles of Anti-LT sIgA1, sIgA2 and IgG under 
Various Conditions  
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To better summarize and compare the stability results described above as a 
function of solution pH and molecule type (sIgA1, sIgA2, IgG1), a “relative stability 
index” was determined (Figure 10). Briefly, Figure 10 displays the results of the relative 
stability comparisons between the three anti-LT mAbs in terms of conformational 
stability at pH 7.2 and 3.0 (vs. temperature and vs. GdnHCl) as shown in Figure 10A, 
the relative apparent solubility at pH 7.2 and 3.0 as shown in Figure 10B, and finally, the 
stability profile during incubation in the in vitro digestion model (37°C, pH 3.5 with 
pepsin) as shown in Figure 10C. For each condition, three values (1, 2, and 3) were 
assigned to each of the three mAbs corresponding to their relative rank ordering in 
stability (highest, intermediate, and lowest). These values in Figure 10A and B were 
determined from the replotting of Figure 6 data as shown in Supplemental Figure S1.  
As shown in Figure 10A (top panel), the physical properties of the three mAbs at 
pH 7.2 were ranked ordered as described above, and then the results were combined 
(bottom panel). It can be seen that sIgA1 scored as having the best physical properties 
(combination of results from thermal and denaturant unfolding as well as relative 
solubility), followed by sIgA2 with intermediate behavior, and IgG1 as the least desirable 
properties overall. The same evaluation was carried out at pH 3.0 as shown in Figure 
10B, and the same relative rank ordering of desirable physical properties was calculated 
at pH 3.0 with sIgA1 > sIgA2 > IgG1. Results of relative stability index during incubation 
in the in vitro gastric digestion model are shown in Figure 10C based on rank ordering 
the results from the ELISA, SDS-PAGE and SEC analyses (see Figures 7, 8, 9). The 
sIgA1 and sIgA2 mAbs showed an overall similar ranking in terms of relative stability 
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under conditions that mimic oral delivery, with IgG1 displaying the lowest stability overall 
under these conditions.  
 
DISCUSSION 
Monoclonal antibodies (mAbs) are widely used for treating a variety of diseases 
especially pre-exposure prophylaxis (PreP) for infectious diseases, autoimmune 
disorders, and cancers.52 Approximately 70 mAbs are now approved for various 
therapeutic uses by regulatory agencies, and the vast majority are comprised of the 
IgG1 antibody subtype and are administered to patients by parenteral injection 
(intravenous or subcutaneous routes) for systemic delivery. From a product 
development point of view, key structural attributes of this category of antibody drugs 
(parenterally administered IgG1 mAbs) are now well-established including determination 
of primary structure and post-translational modifications (e.g., glycosylation), size and 
aggregation propensity, higher-order structural integrity and in vitro potency evaluations 
including antigen binding, cell-based assays, and in some cases, effector function 
assays.53-55 Once established, these structural attributes can be closely monitored 
during manufacturing, storage and transport of an IgG1 mAb to ensure product quality.  
Analytical/Formulation Development Challenges for Orally Administered sIgA mAbs 
In this work, we have evaluated some unique analytical and formulation 
development challenges with a different class of monoclonal antibodies (secretory IgAs, 
sIgAs) for administration by a different route (oral administration for local delivery) for a 
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different application (passive immunization to protect against enteric diseases in the 
developing world). Specifically, sIgA1, sIgA2 and IgG1 mAbs targeting heat labile 
enterotoxin (LT), a major virulence factor of Enterotoxigenic E. coli (ETEC), were 
examined in this work. The potential therapeutic use of sIgAs for passive immunization 
are of particular interest since they are the predominant immunoglobulin isotype in 
tears, saliva, breast milk, colostrum, and mucosal surfaces such as the gastrointestinal 
as well as genitourinary tracts.26 Regardless of ultimate success of using anti-LT sIgA 
mAbs for passive immunization against ETEC infections in vivo (preclinical animal 
studies ongoing), generation of milligram quantities of these anti-LT sIgA monoclonal 
antibodies provided the opportunity to evaluate sIgA mAbs in terms of pharmaceutical 
development challenges including preformulation characterization, stabilization and 
formulation for oral delivery.  
One key challenge for performing the preformulation characterization and 
stability evaluations reported in this work was the limited amount of purified sIgA 
material available. Given the current preclinical stage of development, only ~5-10 mg of 
material was available for this work. To this end, we first evaluated a series of analytical 
tools to assess structural integrity, post-translational modifications, size/aggregation, 
conformational stability, relative solubility and antigen binding activity with minimal 
material. In addition, we aimed to perform many of these assessments under conditions 
of neutral pH as well as more acidic pH (using a scaled down version of an in vitro 
gastric digestion model; see below). The main objective was to not only better 
understand the key structural attributes of sIgA mAbs when formulated for oral 
administration, but also to compare the results to the much more widely studied IgG1 
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mAb. This was accomplished by examining three anti-LT mAbs produced in CHO cells 
(i.e., sIgA1, sIgA2 and IgG1).  
Key Structural Attributes of sIgAs as Potential Orally-Delivered Drug Candidates 
A combination of LC-MS peptide mapping, N-glycan analysis and size 
comparisons under denaturing (SDS-PAGE) and non-denaturing conditions (SEC and 
SV-AUC) confirmed the increased structural complexity and heterogeneity of sIgA 
compared to IgG1 mAbs including their multi-polypeptide chain composition, higher 
molecular weight of dimeric sIgA mAbs, as well as their more abundant and complex 
glycosylation patterns. In addition, a larger relative percent of higher molecular weight 
(HMW) species was demonstrated for both the sIgA1 and sIgA2 mAbs vs. the IgG1 
mAb. The sIgA mAbs were more physically stable and pepsin-resistant (during 
incubation at 37°C, pH 3.5), and thus are likely more suitable for patient administration 
by oral delivery. This result is not unexpected considering sIgA is the most abundant 
antibody isotype in external secretions and mucosal membranes.19,56 Based on these 
preformulation characterization results, three key structural attributes for sIgA mAbs 
were identified including (1) carbohydrate content including N-glycan oligosaccharide 
profiles, (2) size heterogeneity/aggregation, and (3) stability profile under in vitro 
conditions that mimic oral delivery as discussed in more detail below. The monitoring of 
these structural attributes during process development and scale-up geared toward 
lowering the cost of producing sIgAs (while maintaining product quality) will be of great 
importance to the overall success of this passive immunization approach. 
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When considering the total amount of carbohydrate and N-linked oligosaccharide 
profiles, significant differences were observed between sIgA1 vs. sIgA2 (~18% total 
carbohydrate with 23-24 different N-glycan oligosaccharides) vs. IgG1 (~1% total 
carbohydrate with 5 different N-glycan oligosaccharides) expressed in CHO cells. It is 
expected the glycosylation pattern for sIgA mAbs will be a critical structural attribute to 
monitor since their heavily glycosylated nature facilitates antibody binding to various 
pathogens and receptors.38 For example, the N-glycans on the J chain are usually 
required for dimer or oligomer formation of sIgAs, and can also bind to polymeric 
immunoglobulin receptors (plgR).57 The secretory components (SC) of sIgAs are also 
heavily glycosylated, and the wide range of N-glycans on the SC creates diverse glycan 
epitopes, which can function as targets for lectins and bacterial adhesins.38,58,59 As a 
result, glycosylated SC can inhibit bacteria adhesion and prevent the establishment of 
an infection.59,60 In addition, the galactose-terminating N-glycans are potential ligands 
for the asialoglycoprotein receptor (ASGP-R) that could mediate the clearance and half-
life of IgAs.61,62 Although a relatively simpler N-glycan profile was obtained for IgG1, 
these glycans are required for maintaining protein stability, increasing solubility, 
maintaining Fc effector functions, and receptor binding (e.g., Fcγ).38,63 In terms of future 
work, analysis of the total carbohydrate content by mass spectrometry methods prior to 
sample manipulation will be of interest to determine. In addition, identification of the O-
glycosylation profile for sIgA mAbs will need to be evaluated, both for process 
consistency as well to better understand the role it may play in pathogen binding. 
Finally, batch-to-batch variability of the glycan profiles as well as their effects on sIgA 
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mAb stability (in terms of overall flexibility of the hinge region and protection of the hinge 
region from protease digestion38) will be important topics to further study.  
As for size heterogeneity of these three anti-LT mAbs, the IgG1 mAb was 
relatively more homogeneous containing 91-96% main peak with smaller amounts of 
higher molecular weight (HMW) species (4-9%) as measured by SE-HPLC and SV-
AUC. In contrast, both sIgA mAbs contained lower amounts of the main peak (dimeric 
sIgA at 50-57% for sIgA1 and 18-22% for sIgA2), and had higher levels of HMW 
species (43-50% for sIgA1 and 78-82% for sIgA2). Since there are several cysteine 
residues in each J-chain that usually form both inter- and intra-chain disulfide bonds, it 
is likely that disulfide bond scrambling (leading to formation of inter-chain disulfide 
bonds between the tailpiece and cysteine residues in the heavy chains) can occur.64,65 
Thus, the J chain has the potential to be a hotspot for cross-linking oligomers for 
sIgAs.64-67 In this work and consistent with published data, the J-chain was not detected 
by SDS-PAGE under reducing or non-reducing conditions68, although it was readily 
identified by LC-MS peptide mapping. One possible reported explanation is that the J-
chain remains associated with light chain of sIgAs as a complex and thus co-migrated 
with the light chain68,69, although we did not observe such a complex by SDS-PAGE in 
terms of MW migration in this work (Figure 1B).  
It is expected that the presence and formation of HMW species observed in this 
work will be a key structural attribute to monitor in the future with various preparations of 
sIgAs. Aggregation is of concern with parenterally administered mAbs due to the loss of 
potency and the potential for anti-drug immune responses that limit efficacy and 
potentially affect safety.70 However, it is not known to what extent this would be a 
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concern during oral delivery of sIgAs. In fact, the polymeric nature of sIgA may not 
necessarily be a negative attribute in terms of efficacy during oral delivery for passive 
immunization (as long as the mAb-based drug itself is not lost due to irreversible 
precipitation and no unwanted immune responses are generated). The biological 
potency of polymeric sIgAs has been previously reported to be preserved along with 
some protease resistance.71 Furthermore, polymeric sIgA may elicit intracellular 
signaling by binding to pIgRs, and potentially inhibit intracellular virus replication.72-74 
Interestingly, polymeric sIgA can display greater activity, when compared to dimeric 
sIgA, with regards to neutralizing toxins or whole bacterial cells, such as neutralizing 
proinflammatory antigens located in the apical recycling endosome.64,75,76 In addition, it 
has been recently revealed that the functionality of an sIgA against influenza A viruses 
is notably enhanced in a specific polymeric form (tetrameric) due to significant 
improvement of target breadth.77 Since it is likely that both covalent crosslinking as well 
as non-covalent interactions between sIgA molecules play a key role in formation of 
HMW species, future work will focus on better understanding the mechanism(s) of 
aggregate formation during production and during long-term storage. The batch-to-
batch variability of the percent content and size distribution of the HMW species for 
various sIgAs mAbs will also be of interest to further evaluate (both at time zero and 
during storage) as well as determining the effect of sIgA oligomerization on biological 
activity.  
Stability Profiles and Formulation Challenges of sIgA mAbs for Oral Delivery 
The last key structural attribute identified in this work is the stability profile of 
sIgA1, sIgA2 and IgG1 mAbs under in vitro conditions that mimic oral delivery. We 
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adapted a previously reported in vitro gastric model for evaluating the fate of various 
food products and supplements during transit through the digestive tract (see 
Methods).30 Due to limited material availability, we focused our experiments on a scaled 
down version of the gastric phase of digestion, since this is the first major stage that is 
encountered in vivo with pepsin readily degrading proteins.78 As a preliminary 
formulation assessment, we also tested a bicarbonate formulation buffer, which has 
been successfully used as part of a rotavirus vaccination program during oral 
vaccination.34 The stability profile of the three anti-LT mAbs was monitored by ELISA, 
SDS-PAGE and SEC. Although possessing a trend toward relatively lower binding 
affinity at time zero, sIgA mAbs showed greatly improved stability of antigen binding 
properties as measured by ELISA over 24 hr incubation in the in vitro gastric digestion 
conditions (37°C, pH 3.5 in the presence of pepsin). The major digestion product after 
pepsin digestion was the F(ab’)2 fragment for each of the three mAbs as determined by 
SDS-PAGE and SE-HPLC. Nevertheless, the antigen binding values varied over time 
between the three mAbs. These observations indicate that not all F(ab’)2 fragments 
retained antigen binding activity to the same extent in comparison to the full length, 
undigested mAbs. Potential conformational structure changes, allosteric effects, and/or 
glycosylation may influence these properties.56,79-82  
In terms of future work with the scaled-down in vitro digestion model, sIgA 
stability profiles under conditions that mimic sequential digestion (e.g., oral, gastric, and 
intestinal phases) will be evaluated to better understand the stability profile of sIgA 
candidates under varying conditions that mimic the entire oral delivery pathway for local 
delivery to the GI tract. In addition, analytical techniques with better sensitivity and 
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higher resolution, such as mass spectrometry, will be applied to assess the most 
sensitive sites for proteolytic digestion of the sIgA mAbs in the in vitro digestion model. 
In addition, this scaled-down in vitro digestion model can be utilized in the future to 
screen for formulation excipients that may help improve stability and retain potency 
during oral delivery. The concept was established in this work by demonstrating the 
protective effect of co-addition of bicarbonate buffer in terms of stabilizing the three anti-
LT mAbs during incubation in the in vitro gastric digestion model (see Figures 7, 8 and 
9).  
Smaller molecular weight protein therapeutic drugs (e.g., insulin) have been 
evaluated for systemic use by oral delivery83-85, and face several significant barriers 
including poor stability (due to acidic pH and digestive enzymes) and low bioavailability. 
It has been reported that advanced drug delivery systems can be used to improve oral 
delivery of insulin, e.g. polymeric nanoparticles, micelles, liposomes, microspheres, or 
pH responsive complexation gels.83,85-87 In contrast, the goal of this work is local 
delivery of the sIgA mAbs to bind and neutralize Enterotoxigenic E. coli (ETEC) in the 
GI tract. Thus, passive immunization with sIgA mAbs may be a more successful 
approach than systematic delivery by the oral route of administration. However, for 
passive immunization applications in low-income and developing countries, low cost 
formulations of sIgA mAbs for treatment of diarrheal diseases is critical, making the use 
of complex formulations such as advanced delivery technologies described above less 
desirable.  
To this end, future sIgA mAb formulation development efforts will focus on 
simple, low-cost liquid formulations that provide good long-term storage stability (ideally 
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at room temperature), and concomitantly provide protection from acidic pH/proteases 
degradation during oral delivery, in a single final container. Ideally, such a low-cost 
liquid dosage form could be designed as an oral supplement during infant feeding. 
Based on results of this work, the commonly used PBS buffer formulation of sIgAs is not 
sufficient to meet these goals, so improved formulations will certainly need to be 
identified including optimization of solution pH and addition of excipients to minimize 
aggregate formation during processing as well as during long-term storage. In the 
shorter term, to facilitate first-in-human clinical studies of orally delivered sIgA mAbs in 
adults, stable refrigerated/frozen preparations of sIgAs, combined with bed-side mixing 
with additives to protect during oral delivery (for adults), can be considered. Thus, the 
analytical tools utilized in this work were selected for their ability to monitor key 
structural attributes of sIgA mAbs from a formulation development perspective. These 
tools can be used to not only ensure therapeutic sIgA mAb drug candidates are 
reproducibly produced, but also can be formulated in a low-cost dosage form for oral 
administration, to pursue the long term goal of protecting infants in the developing world 
against certain enteric diseases by targeted passive immunization. 
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FIGURE LEGENDS 
Figure 1. Structural overview and SDS-PAGE purity analysis of sIgA1, sIgA2 and IgG1 
mAbs used in this study. (A) Schematic representation of immunoglobulin domains 
within sIgA1, sIgA2, and IgG1 antibodies. The LC, HC, SC and J polypeptide chains, 
along with sites of post-translational N- and O-linked glycosylation, are indicated (see 
text). The sIgA1 and sIgA2 antibody species shown are commonly referred to as 
dimeric sIgA (see text). (B) Representative SDS-PAGE analysis of three anti-LT mAbs 
under non-reducing and reducing conditions with and without removal of N-glycans by 
PNGase F treatment. The molecular weight markers are on the far left lane. All bands 
assignments were based on molecular weight migration only. 
Figure 2. Representative LC-MS peptide mapping chromatograms of sIgA1, sIgA2 and 
IgG1 to confirm the primary sequence of each polypeptide chain in each mAb and to 
evaluate for chemical post-translational modifications (see text). (A) Representative LC 
base peak chromatograms of each mAb after trypsin digestion; (B) Percentage primary 
sequence coverage on each polypeptide chain found in each of the three mAbs. 
Figure 3. Glycosylation analysis of sIgA1, sIgA2 and IgG1 mAbs produced in CHO 
cells. (A) Total carbohydrate content, and (B, C, D) representative chromatographic 
profiles of Fluor-MS N-linked glycans removed from the mAbs are shown for (B) sIgA1, 
(C) sIgA2, and (D) IgG1. Fluorescence and mass spectrometry results are indicated and 
peaks are numbered as a series of different N-glycans. See Figure 4 for summary of 
results. All data are presented as mean ± SD; n = 3.  
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Figure 4. Identification and percent composition of each N-glycan type found in sIgA1, 
sIgA2 and IgG1 mAbs (produced in CHO cells) as determined by Fluor-MS N-linked 
glycan analysis. The total number of N-glycans, their respective oxford notations and 
structures,88 as well as the relative percentage of the total N-glycans for each mAb is 
shown. See Figure 3 for representative chromatograms. All data are presented as an 
average value; n = 3. 
Figure 5. Size analysis of anti-LT sIgA1, sIgA2 and IgG1 mAbs as measured by SV-
AVC and SE-HPLC. (A) Representative SV-AUC and (B) representative SE-HPLC 
analysis of the three mAbs. Two major categories (main peak and HMW species) were 
assigned based on sedimentation coefficient values and retention time values, 
respectively. Note, a different SEC column was used for IgG1 vs. the two sIgAs mAbs. 
(C) Relative amount of main peak and HMW species calculated based on the total peak 
areas for both SV-AUC and SE-HPLC. Estimated molecular weight determinations were 
calculated as shown in Supplemental Table S1. Percent species were determined as 
average value; n = 2 for SV-AUC and n = 3 for SE-HPLC, with range and standard 
deviation values of 0.1 to 4.4% and from 0.1 to 0.6%, respectively. 
Figure 6. Comparison of conformational stability and relative apparent solubility profiles 
of anti-LT sIgA1, sIgA2, and IgG1 mAbs at pH 7.2 vs. pH 3.0. (A) Thermal unfolding as 
measured by the shift of MSM peak position as a function of temperature, and (B) 
GdnHCl unfolding as a function of denaturant concentration, both measured by intrinsic 
Trp fluorescence spectroscopy. (C) Relative protein concentration of each mAb as a 
function of PEG10,000 concentration (w/v) as measured by UV-visible spectroscopy. All 
data are presented as mean ± SD; n = 3. 
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Figure 7. Comparison of LT-antigen binding curves for the three anti-LT mAbs after 
incubation in the in vitro gastric digestion model as measured by ELISA including (A) 
sIgA1, (B) sIgA2, and (C) IgG1. (D) Comparison of the relative percent LT antigen 
binding remaining for each of the three mAbs based on normalization to the time zero 
binding curve (with or without bicarbonate buffer) are displayed (mean ± SD; n = 3). 
Figure 8. Comparison of structural integrity of the three anti-LT mAbs after incubation in 
the in vitro gastric digestion model as measured by SDS-PAGE: (A) sIgA1, (B) sIgA2, 
and (C) IgG1. Representative SDS-PAGE results of digested mAb samples by time 
course with or without co-addition of sodium bicarbonate buffer (0.03 M trisodium citrate 
and 0.3 M sodium bicarbonate at pH 8.5) (D) Comparison of the relative percent intact 
species remaining over time for each of the three mAbs based on densitometry analysis 
of the main species (intact mAb) normalized to values at time zero (mean ± SD; n = 3). 
Figure 9. Comparison of the structural integrity of the three anti-LT mAbs during 
incubation in the in vitro gastric digestion model as measured by SE-HPLC: (A) sIgA1, 
(B) sIgA2, and (C) IgG1. Representative SE-HPLC chromatograms with UV 214nm 
detection are displayed. Samples were incubated in presence of immobilized pepsin as 
a function of time and analyzed after removal of pepsin-agarose. (D) Comparison of the 
relative percent intact species remaining over time for each of the three mAbs based on 
main SEC peak integration and normalization to time zero (mean ± SD; n = 3). 
Figure 10. Comparison and rank ordering of desirable physical properties and stability 
profiles of sIgA1, sIgA2 and IgG1 mAbs (“relative stability indexes”; see text) including 
(A) physical properties at pH 7.2, (B) physical properties at pH 3.0, and (C) relative 
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stability after incubation at 37°C, pH 3.5 with pepsin in the in vitro gastric digestion 
model. See Figure 6 and Supplemental Figure S1 for data sets used in (A) and (B). See 
Figures 7-9 for data sets used to rank order mAbs in (C).  
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